Renae L. Wilson

Stimuli-responsive bioengineered platforms for precision cancer therapy

The evidence supports a conceptual transition from passive nanocarriers to programmable therapeutic systems capable of aligning therapeutic action with the spatial, temporal, and biological heterogeneity of tumors, but translation remains constrained by formulation complexity, incomplete standardization, limited long-term safety and biodistribution data, insufficient penetration into protected tumor niches, and the need for clinically relevant models that capture patient-level heterogeneity.